Revolution Medicines, Inc. (NASDAQ:RVMD) Stock Position Decreased by US Bancorp DE

US Bancorp DE lessened its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD) by 16.8% in the 3rd quarter, Holdings Channel reports. The firm owned 2,455 shares of the company’s stock after selling 496 shares during the quarter. US Bancorp DE’s holdings in Revolution Medicines were worth $111,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in RVMD. GAMMA Investing LLC grew its stake in Revolution Medicines by 55.8% in the 3rd quarter. GAMMA Investing LLC now owns 620 shares of the company’s stock valued at $28,000 after buying an additional 222 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in Revolution Medicines by 10.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,378 shares of the company’s stock valued at $131,000 after buying an additional 320 shares during the period. Amalgamated Bank grew its stake in shares of Revolution Medicines by 7.4% in the 2nd quarter. Amalgamated Bank now owns 5,272 shares of the company’s stock valued at $205,000 after purchasing an additional 365 shares during the period. Headlands Technologies LLC raised its holdings in shares of Revolution Medicines by 140.9% in the 1st quarter. Headlands Technologies LLC now owns 1,513 shares of the company’s stock worth $49,000 after buying an additional 885 shares in the last quarter. Finally, Clear Harbor Asset Management LLC lifted its position in shares of Revolution Medicines by 10.2% during the 2nd quarter. Clear Harbor Asset Management LLC now owns 11,224 shares of the company’s stock worth $436,000 after buying an additional 1,036 shares during the period. Institutional investors own 94.34% of the company’s stock.

Revolution Medicines Stock Performance

Shares of NASDAQ:RVMD opened at $55.13 on Friday. Revolution Medicines, Inc. has a 52 week low of $20.51 and a 52 week high of $62.40. The firm has a market cap of $9.27 billion, a PE ratio of -15.63 and a beta of 1.40. The firm’s fifty day moving average is $48.87 and its 200-day moving average is $43.81.

Revolution Medicines (NASDAQ:RVMD) last announced its earnings results on Wednesday, November 6th. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.05). During the same period in the previous year, the business earned ($0.99) earnings per share. Sell-side analysts forecast that Revolution Medicines, Inc. will post -3.51 EPS for the current year.

Insiders Place Their Bets

In other Revolution Medicines news, insider Stephen Michael Kelsey sold 16,666 shares of Revolution Medicines stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $49.49, for a total value of $824,800.34. Following the completion of the sale, the insider now directly owns 264,408 shares in the company, valued at approximately $13,085,551.92. The trade was a 5.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Mark A. Goldsmith sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $44.93, for a total transaction of $449,300.00. Following the sale, the insider now directly owns 300,170 shares of the company’s stock, valued at approximately $13,486,638.10. This trade represents a 3.22 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 127,866 shares of company stock worth $6,355,624. 8.00% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages have recently weighed in on RVMD. Piper Sandler raised their target price on Revolution Medicines from $57.00 to $70.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Guggenheim increased their price objective on Revolution Medicines from $72.00 to $82.00 and gave the stock a “buy” rating in a report on Monday, October 28th. Oppenheimer upped their price objective on Revolution Medicines from $55.00 to $60.00 and gave the stock an “outperform” rating in a research note on Monday, October 28th. Barclays upped their price objective on Revolution Medicines from $54.00 to $60.00 and gave the company an “overweight” rating in a research note on Friday, September 27th. Finally, Wedbush restated an “outperform” rating and set a $59.00 price objective on shares of Revolution Medicines in a report on Thursday, August 8th. Eleven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $61.00.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.